Business
Medicenna to Present at Upcoming Scientific Conferences
Medicenna to Present at Upcoming Scientific Conferences Canada NewsWire TORONTO ...
About this update from Medicenna Therapeutics Corp.
[{"type":"text","content":"\n\n\n\nMedicenna to Present at Upcoming Scientific Conferences\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prngen3{\nBORDER-TOP:1pt; BORDER-RIGHT:1pt; VERTICAL-ALIGN: TOP; BORDER-BOTTOM:1pt; TEXT-ALIGN: LEFT; PADDING-LEFT:0.50em; BORDER-LEFT:1pt; PADDING-RIGHT:0.50em\n}\n.prngen5{\nBORDER-TOP:black 0pt; BORDER-RIGHT:black 0pt; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM:black 0pt; TEXT-ALIGN: LEFT; PADDING-LEFT:0.50em; BORDER-LEFT:black 0pt; PADDING-RIGHT:0.50em\n}\n.prngen4{\nBORDER-TOP:black 0pt; BORDER-RIGHT:black 0pt; VERTICAL-ALIGN: TOP; BORDER-BOTTOM:black 0pt; TEXT-ALIGN: LEFT; PADDING-LEFT:0.50em; BORDER-LEFT:black 0pt; PADDING-RIGHT:0.50em\n}\n.prntblns{\nBORDER-TOP: 1pt; BORDER-RIGHT: 1pt; BORDER-COLLAPSE: collapse; BORDER-BOTTOM: 1pt; BORDER-LEFT: 1pt\n}\n.prnsbt0{\nBORDER-TOP:0pt\n}\n.prnbcc{\nBORDER-COLLAPSE: COLLAPSE\n}\n.prnsbl0{\nBORDER-LEFT:0pt\n}\n.prnsbb0{\nBORDER-BOTTOM:0pt\n}\n.prnsbr0{\nBORDER-RIGHT:0pt\n}\n\n\n\n\n\n\n\nCanada NewsWire\nTORONTO and HOUSTON, Nov. 7, 2018\n\n\n\nTORONTO and HOUSTON, Nov. 7, 2018 /CNW/ - Medicenna Therapeutics Corp. (\"Medicenna\" or the \"Company\") (TSX: MDNA; OTCQB: MDNAF), a clinical stage immuno-oncology company, will be presenting an update on previously announced data from the Company's MDNA109 and MDNA55 programs at the following conferences:\n33rd Annual Meeting of the Society for Immunotherapy of Cancer (SITC) held from November 7 to 11, 2018 \nTitle:\nPreclinical characterization of IL-2 Superkines engineered with biased CD8+T cell stimulating properties\nPoster #:\nP415\nDate/Time:\nFriday, November 9th 2018 from 12:45 pm to 6:30 pm EST\nLocation:\nHall E, Walter E. Washington Convention Center in Washington, D.C. \n \n23rd Annual Meeting of the Society of Neuro-Oncology (SNO) held from November 15 to 18, 2018 \nPresenter: \nDr. Achal Singh Achrol, MD; Director of the Neurosurgery Clinical Trials Program and Chief of the Glioma Surgery Program at the John Wayne Cancer Institute and Pacific Neuroscience Institute\nTitle:\nIntratumoral Delivery of MDNA55, an Interleukin­4 Receptor Targ...